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Simultaneous integrated boosta b s t r a c t
Background and purpose: The safety of a simultaneous integrated boost (SIB) in combination with prone
hypofractionated whole-breast irradiation (WBI) was investigated.
Materials and methods: 167 patients were randomized between WBI with a sequential boost (SeB) or SIB.
All patients were treated in prone position to 40.05 Gy in 15 fractions to the whole breast. In the control
arm, a SeB of 10 Gy in 4 fractions (negative surgical margins) or 14.88 Gy in 6 fractions (transsection) was
prescribed. In the experimental arm a SIB of 46.8 or 49.95 Gy (negative and positive surgical margins,
respectively) was prescribed.
Results: Patient age was the only significantly different parameter between treatment arms with patients
in the SIB arm being slightly older. In both arms, 6/83 patients developed moist desquamation. Grade 2/3
dermatitis was significantly more frequent in the SeB arm (38/83 vs 24/83 patients, p = 0.037). In the SIB
and SeB arm, respectively, 36 patients (43%) and 51 patients (61%) developed pruritus (p = 0.015). The
incidence of oedema was lower in the SIB arm (59 vs 68 patients), but not statistically significant
(p = 0.071).
Conclusions: The primary endpoint, moist desquamation, was not significantly different between treat-
ment arms.
 2016 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 122 (2017) 30–36Moderate hypofractionation in 15 or 16 fractions has been gen-
erally accepted as a valid alternative for the historical schedules of
25–30 fractions for whole-breast irradiation (WBI) after breast
conserving surgery (BCS). With a median follow-up of 9.9 years,
the UK START-B trial showed no significant difference in locore-
gional control between a hypofractionated schedule of 40.05 Gy
in 15 fractions and a normofractionation scheme of 50 Gy in 25
fractions [1]. The Canadian schedule of 42.5 Gy in 16 fractions
was also not inferior to the 50 Gy/25 fractions after 10 years of
follow-up [2]. Aside from the obvious advantage of shortening
the overall treatment time from 5 weeks to 3 weeks, both for the
patient and the radiotherapy department, there might be some
radiobiological advantages too. In the START-B trial, breast shrink-
age, telangiectasia and breast oedema were significantly less fre-
quent in the hypofractionation group. Better disease free survival
and overall survival were also reported in the 15 fractions group,due to less distant relapses. The superiority of hypofractionation
on survival and cosmesis was not observed in the Canadian trial.
While moderate hypofractionation schemes are slowly replac-
ing normofractionation schemes worldwide for WBI, the role of a
boost dose after hypofractionation is still unknown. After nor-
mofractionation, a boost to the region at high-risk for relapse has
been shown to improve local control [3]. In the START trials, about
40% of patients received a boost of 10 Gy in 5 fractions [1]. In the
Canadian trial, boost treatment was not allowed, which might
explain the higher rate of local relapse seen in the subgroup of
patients with a high-grade tumour treated by hypofractionation
[2]. While there is some discussion about the role of a boost in
patients over 60 years, it seems not recommendable to omit the
boost in younger patients [3]. A sequential boost (SeB) is typically
delivered in 4 to 8 extra fractions which again prolongs the overall
treatment time by 1–2 weeks. A so-called simultaneous integrated
boost (SIB) technique allows delivering the boost simultaneously
with the whole-breast treatment, avoiding unnecessary treatment
prolongation.
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comparative SeB-SIB treatment planning studies [4–7]. The combi-
nation of a SIB with normofractionation schemes does not seem to
increase toxicity either [8,9]. The trials on hypofractionated SIB
treatment are scarce. Two non-comparative trials describe accept-
able toxicity, cosmesis and quality of life [10,11]. One randomized
controlled trial in 69 patients showed less toxicity in the SIB arm
after 1 year of follow-up, while heart and lung function were not
impaired [12]. Recently, the group of Sylvia Formenti published
data on 400 patients treated to 40.05 Gy in 15 fractions to the
breast, randomized between a daily concomitant boost of 0.5 Gy
or a weekly 2 Gy boost. Acute grade 2 and long-term toxicity were
comparable in both groups with a median follow-up of 45 months
[13]. Long-term follow-up data of SIB treatment are limited, but
local control after 5 year seems to be acceptable [14,15].
With the exception of the patients treated at the New York
University School of Medicine [13,15], all patients in the above-
mentioned studies were treated in supine position. Although not
generally accepted yet, prone position is an alternative for WBI
with or without a boost. The merits of prone over supine position
include: better avoidance of lung tissue (in all patients) and heart
tissue (in the majority of patients) [16–18], better dose homogene-
ity with less hot spots and a favourable toxicity profile, especially
in large-breasted females [19]. Disadvantages include the complex
and uncomfortable setup and reduced reproducibility. Both centres
involved in this trial, have experience with prone position in com-
bination with hypofractionation for WBI without lymph node irra-
diation. The aim of this study was to investigate whether a SIB can
safely be used in combination with prone hypofractionated WBI.Materials and methods
Patients
As illustrated in the Consort diagram (Fig. 1), 168 patients were
included after breast conserving surgery for early-stage breast car-
cinoma. 151 patients were treated at Ghent University Hospital
(UZ Gent) and 17 at Liège University Hospital (CHU Liège). The
study was approved by the Ethics Board of both hospitals and reg-
istered at clinicaltrials.gov (NCT01973634). Exclusion criteria
were: mastectomy, lymph node irradiation, no boost dose planned
according to the institution’s practice guidelines, bilateral breast
irradiation, patient unable to be treated in prone position, age
<18 years, pregnant or breast feeding. At the beginning of the trial,Randomized (n
• CHU Liège 
• UZ Gent (n
Allocated to SeB (n=84)
• CHU Liège (n=9)
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Fig. 1. CONSORpatients with a left-sided tumour and European cup size A or B
were also excluded because a higher heart dose was feared in
prone position in this population of small-breasted patients
[16,17]. From October 2013, all left-sided patients received prone
breath hold [20] during treatment if mean heart dose was P2 Gy
or the maximum heart dose (D02) was P10 Gy. D02 was defined
as the dose received by 2% of the heart volume. An amendment
to the protocol was approved by the Ethics Board, allowing
patients with A and B cup to be included. For 1 patient allocated
to the experimental treatment, radiation treatment was cancelled
because axillary lymph nodes were detected on the planning CT.
After axillary lymph node dissection, she did no longer meet the
inclusion criteria of the trial because lymph node irradiation was
required. This patient was treated at UZ Gent.Radiotherapy
Patients were treated on a modified AIO Prone Breastboard at
UZ Gent [19] and on the Sagittilt Prone Breast Solution at CHU
Liège (both Orfit Industries, Wijnegem, Belgium). All patients were
treated in prone position to 40.05 Gy in 15 fractions. The boost was
delivered sequentially (84 patients) or simultaneously (83
patients) according to randomization. In the SeB arm the boost
was delivered in 4 fractions of 2.5 Gy when negative surgical mar-
gins were achieved. In case of close or positive surgical margins,
the boost dose consisted of 14.88 Gy in 6 fractions of 2.48 Gy.
Patients of the experimental arm received a SIB to the tumour
bed of 3.12 Gy (negative surgical margins) or 3.33 Gy (positive sur-
gical margins) per fraction to a total cumulative dose of 46.8 Gy or
49.95 Gy.
The clinical target volume for boost irradiation (CTVboost) was
defined by the radiation oncologist using all available preoperative
and postoperative information like surgical clips, seroma, preoper-
ative imaging, the surgical report and the histopathology report.
For WBI the whole breast was delineated by the aid of a copper
wire placed around the palpable breast tissue in prone position.
A planning target volume for WBI (PTVWBI) extending in air was
created to account for swelling of the breast and respiratory move-
ment. An inverse planned intensity modulated radiotherapy
(IMRT) technique was used. During optimization a virtual bolus
was used to assure skin flash [21]. For the final dose calculation
(without the virtual bolus), dose was prescribed to the PTVopt. This
is an optimization structure created by removing the in-air part of
the PTVWBI and the first 7 mm underneath the skin to remove the=168)
(n=17)
=151)
Allocated to SIB (n=84)
• CHU Liège (n=8)
• UZ Gent (n=76)
eceived SIB (n=83)
id not receive SIB (radiaon treatment canceled) (n=1)
ost to follow-up (n=0)
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T diagram.
32 RCT prone breast irradiation with SIBbuild-up region of photon beams [22]. In both treatment arms, the
majority of patients received one medial and one lateral beam for
WBI and 2–3 beams (mostly 1 beam with a table isocentre rota-
tion) for boost irradiation. The 26 patients treated with breath hold
were planned with a comparable intensity modulated arc therapy
(IMAT) technique with very small (2–3) medial and lateral arcs.
IMAT was only used for practical reasons: faster delivery and
therefore less breath holds needed than with IMRT.
In the SeB arm treatment was planned in 2 phases. First, a med-
ian dose of 40.05 Gy in 15 fractions was prescribed to the PTVopt,
while it was assured that 95% of the PTVopt received 38 Gy and
no more than 5% received 42 Gy. In the second phase, a median
boost dose of 10 Gy/4 fractions or 14.88 Gy/6 fractions was pre-
scribed to the PTVboost (5 mm isotropic expansion from CTVboost).
Planning objectives included a D95 of 95% and a D05 of 105% of
the prescription dose. D02 was defined as the dose received by
2% of a structure’s volume. D95 was defined by the dose received
by 95% of a structure’s volume. For comparative analysis, dose
parameters in the SeB arm were calculated on the summed dose
distribution of the WBI phase and the boost phase.
For the patients treated with a breath hold technique a summed
dose distribution was calculated on the breath hold CT [23]. A
deformation field (DF) was generated between the breath hold
CT and the shallow breathing CT using the Advanced Medical
Image Registration Engine (ADMIRE) v1.10.01 (Elekta AB, Stock-
holm, Sweden) software package.
In the SIB arm, only one treatment plan was created for 15 frac-
tions. A median dose of 46.8 or 49.95 Gy was prescribed to the
CTVboost with a dose gradient to 40.05 Gy in the first 2 cm around
the CTVboost. This was based on the observation that the chance
of additional tumour foci is highest in the first 2 cm around the ref-
erence tumour [24]. The part of the PTVopt more than 2 cm away
from the CTVboost was defined as a second optimization structure
(optim structure, illustrated in Fig. 2) and here a median dose of
40.05 Gy was aimed for. Again, a D95 of 95% and D05 of 105% ofFig. 2. Illustration of dose prescription in the SIB arm. Dose was prescribed to the
CTV boost. A rim of 2 cm around the CTV boost was created for dose fall off. The
remaining breast tissue, outside the rim, was defined as the optim structure
(shaded area).the prescription dose were intended for the CTVboost and the optim
structure.
Absolute doses in the plan were recalculated to equivalent
doses in 2 Gy fractions (EQD2) for comparison. An a/b value of
10 Gy was used for acute toxicity and of 3 Gy for late side effects.Endpoints
The primary endpoint of the trial was acute moist desquama-
tion. Secondary endpoints included other parameters of acute skin
toxicity (dermatitis, pruritus, oedema), chronic skin toxicity and
cosmesis, quality of life, dose–volume parameters, cost and genetic
predictors for toxicity. This manuscript only reports on acute skin
toxicity and dose–volume parameters.
Sample size calculation for this phase II randomized trial was
done assuming a 10% rate of acute moist desquamation with prone
IMRT. A 15% rate of moist desquamation was considered to be
unacceptable. Using the Wilson score confidence interval test, a
minimum of 165 patients needed to be randomized. The aim was
to include 170 patients (85 in each treatment arm).
Toxicity was measured by a radiation oncologist or a dedicated
nurse, not blinded to the treatment arm, at baseline (on the day of
radiotherapy start), once a week during radiotherapy and at 10–
14 days after treatment start. Desquamation was scored as: none,
dry or moist. Dermatitis was scored using the Common Toxicity
Criteria for Adverse Events (CTCAE) (http://ctep.cancer.gov/proto-
colDevelopment/electronic_applications/ctc.htm); pruritus and
oedema as absent or present.Skin care
Before the start of radiation treatment, patients were informed
about preventive skin care measures: showering and not bathing,
no rubbing on the skin, use of neutral soap. They were also asked
not to use deodorant or any topical applications other than the
ones prescribed by the research team. No preventive topical appli-
cations were used. If skin toxicity presented, a standard treatment
protocol was used in both arms. Ureum 5% in cold cream was pre-
scribed for symptomatic erythema or dry skin. If cold cream was
insufficient, a topical cream with methylprednisolone aceponate
was applied (AdvantanTM). Whenever moist desquamation pre-
sented, MepilexTM bandages were used.Statistics
The SPSS version 23 statistical package was used for analysis.
For comparison between both arms, the Fisher exact test was used
for categorical variables, while the Mann–Whitney U test was used
for continuous variables.Results
Patient and treatment characteristics of the 167 analysed
patients are shown in Table 1. Patients in the control arm were
slightly older (mean age 59.5 years versus 55.7 years in the exper-
imental arm, p = 0.028). The other variables were not significantly
different between treatment arms.
The analysis of dose parameters was done on 163 patients (80
patients in the control arm and 83 patients in the SIB arm). Reasons
for excluding patients were electron boost (2), 3 different plans on
3 different CTs due to irreproducible anatomy changes (1) and
changed treatment arm due to a machine breakdown (1). This lat-
ter patient was excluded from the toxicity analysis as well. She was
randomized in the SeB arm, but after a treatment break, the
responsible radiation oncologist decided to give the remaining
Table 1
patient, tumour and treatment characteristics
SeB (mean ± SD) SIB (mean ± SD) p-Value
Body mass index 26.4 ± 4.26 25.2 ± 4.01 .062
Age (years) 59.5 ± 10.92 55.7 ± 10.54 .028
Breast volume (cc) 833.2 ± 397.06 741.67 ± 374.99 .108
Boost volume (cc) 42.3 ± 27.51 39.8 ± 31.09 .407
SeB (N) SIB (N) p-Value
Localization Left 37 44
Right 47 39 .280
Lymph node dissection No 80 78
Yes 4 5 .746
Positive resection margin No 80 75
Yes 4 8 .248
Hormone therapy No 14 11
Yes 70 72 .665
Chemotherapy No 52 50
Yes 32 33 .875
Trastuzumab No 75 71
Yes 9 12 .493
Abbreviations: SeB = sequential boost, SIB = simultaneous integrated boost, SD = standard deviation, N = number of patients.
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time.
Dosimetry results can be found on the journal’s website in a
Supplementary table. The preset D95 and D05 objectives were
met for the CTVboost for both treatment arms. When comparing
EQD2 for D02 and D05 of the optim structure, significantly higher
doses were found in the SeB group, both for an a/b value of 10 Gy
and 3 Gy (p < .001). Dose distributions for a typical SeB and SIB
plan are shown in Fig. 3. The isodoses of the SeB plan represent
the summation of the plan for WBI and the plan for boost
irradiation.
In both arms, 6/83 patients developed moist desquamation.
Grade 2/3 dermatitis was significantly more frequent in the SeB
arm (38/83 vs 24/83 patients, p = 0.037). In the SIB and SeB arm,
respectively, 36 patients (43%) and 51 patients (61%) developed
pruritus (p = 0.015). The incidence of oedema was lower in the
SIB arm (59 vs 68 patients), but not statistically significant
(p = 0.071).
Fig. 4 shows the evolution of dermatitis, desquamation, pruritus
and oedema over time. In both groups, the incidence of toxicity
was highest in the last week of treatment. At the first follow-up
visit 10 to 14 days after radiation treatment, the number of
patients presenting with no toxicity was increased in both arms.
Grade 2 dermatitis didn’t appear until the 3rd week of treatment,
reaching the highest incidence in week 4 in the sequential boost
arm and in week 3 in the SIB arm. There was one patient in the
SIB arm that had developed a grade 3 dermatitis at the first
follow-up visit after radiotherapy. During the last week of treat-
ment, patchy moist desquamation was already present and this
aggravated to confluent moist desquamation in the first week after
treatment.Discussion
Strong evidence now exists that breast cancer cells are as sensi-
tive to fraction size as healthy tissues [25], justifying the use of
hypofractionation schemes lowering the total dose but increasing
the dose per fraction. WBI in 15–16 fractions is standard practice
in the United Kingdom for several years now. After publication of
the 10 year results of the UK and Canadian randomized trials,
showing excellent efficacy and less long-term side effects of these
schemes compared to more protracted schemes [1,2], the use of
moderate hypofractionation is increasing worldwide. The reduc-
tion in late toxicity might be explained by the reduction of the totaldose. Another radiobiological advantage is the shortened overall
treatment time, possibly improving disease free survival [1]. Of
course, shorter treatment courses with less transportation to the
radiotherapy department are less stressful to the patient and
increase the number of available treatment slots for other patients.
Boost irradiation is again prolonging radiotherapy treatment
and using a SIB is the next logical step to restrict the overall treat-
ment time. From a technical point of view, SIB irradiation is not
that challenging, but a higher dose per fraction is administered
to a part of the breast, which might increase the incidence of acute
and late toxicity. On the other hand, better dose conformity can be
reached if doses to the whole breast and to the boost volume are
optimized simultaneously. Less dose spilling and improved dose
conformity with a SIB have been reported [5,6]. Another drawback
of planning performed sequentially is that hot spots in the first
plan can coincide with hot spots in the second (boost) plan. Mod-
ern treatment planning systems allow taking the dose delivered by
the WBI plan into account when planning the boost, but setup dif-
ferences or anatomy changes are not taken into account.
Two large non-comparative trials report acceptable toxicity of
supine WBI combined with a SIB in 25 or 28 fractions [26,27]. In
the Dutch trial, toxicity and cosmetic outcome are not impaired
after 30 months in 436 patients treated with 3D conformal radio-
therapy with SIB [27]. In the UK trial, retrospective review of 354
patients treated with SIB-IMRT showed favourable acute toxicity
and 3-year cosmesis [26]. These data are confirmed by several
smaller non-comparative studies using different fractionation
schemes [10,11,28–31]. One of the pioneers of prone breast radia-
tion therapy is the New York University School of Medicine. They
have published the 5-year results of 404 patients treated in prone
position with a 15 fractions schedule of 40.5 Gy to the whole breast
and a concomitant boost of 0.5 Gy per fraction to a total dose of
48 Gy [15]. Very limited numbers of more than grade 1 toxicity
were observed with about 80% of patients judging the final cos-
metic result as good or excellent.
Comparative data are scarce. Only 2 randomized controlled tri-
als were found. Very recently, the New York University School of
Medicine reported on 400 prone-treated patients randomized
between a daily concomitant boost and a weekly boost combined
with a hypofractionation scheme [13]. Although, the weekly boost
is not really a sequential boost, the trial has some similarities to
our study, the most important being the fractionation schedule
(40.05 Gy to the breast with a SIB of 47.55 Gy). No difference was
seen in acute or late toxicity [13] with similar quality of life out-
comes [32]. The second randomized trial does not allow to draw
Fig. 3. Dose distribution of a typical SeB patient and a typical SIB patient. The isodoses of the SeB plan represent the summation of the plan for WBI and the plan for boost
irradiation. The CTVboost was delineated in red, the optim structure in blue. High-dose levels are spread out over the optim structure in the SeB plan, while in the SIB plan a
dose gradient is seen between the CTVboost and the optim structure.
34 RCT prone breast irradiation with SIBconclusions on the effect of a SIB since other factors differed
between the SIB and SeB arm [12]. In the control arm, patients
were treated with a normofractionation scheme of 50 Gy in 25
fractions with a SeB of 16 Gy in 8 fractions using conventional
radiotherapy. In the SIB arm, patients were treated with a
hypofractionation scheme of 15 times 2.8–3.4 Gy using helical
tomotherapy. After 2 years, the incidence of toxicity was reduced
from 60% to 30% in the SIB arm; heart and lung function were com-
parable between both arms. Lansu et al. retrospectively investi-
gated the influence of SIB, hypofractionation and oncoplastic
surgery on cosmetic outcome in 125 patients [8]. SIB did not have
an influence on cosmetic outcome, but had a favourable influence
on quality of life. Another non-randomized prospective trial in 60patients showed comparable toxicity of SIB and SeB after 7 months
[9].
The aim of this phase II randomized controlled trial was to eval-
uate whether the combination of a SIB with prone hypofraction-
ated WBI would increase acute toxicity compared to the
routinely used hypofractionation scheme of 40.05 Gy/15 fractions
plus a SeB of 10 Gy/4 fractions or 14.88 Gy/6 fractions. Using an
a/b value of 3.6 Gy as proposed by Yarnold [25] resulted in a 15
fractions schedule with a SIB of 3.12 Gy or 3.33 Gy per fraction.
The rate of moist desquamation, the primary endpoint, was not dif-
ferent between both treatment arms. In both arms, 7% of patients
developed moist desquamation, which is lower than the antici-
pated 10% used for the sample size calculation. If the actual rate
Fig. 4. Evolution of dermatitis and desquamation (upper panel), pruritus and oedema (lower panel) during and after radiation treatment in the sequential boost arm (left) and
the simultaneous integrated boost (SIB) arm (right).
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only 135 patients needed to be randomized to obtain the same
power. The incidence of grade 2/3 dermatitis and pruritus were
reduced by one third in the SIB arm (p = 0.037 and p = 0.015,
respectively). The 2 patients in the SeB arm that received an elec-
tron boost developed no more than grade 1 toxicity.
The favourable acute toxicity profile in the SIB group is consis-
tent with the dosimetry results, showing a significantly lower D02
and D05 in this patient group (p < .001). This is not solely explained
by the difference in fractionation schedule. When an a/b of 10 Gy is
used for acute side effects, a dose of 46.8 Gy in 15 fractions corre-
sponds with an EQD2 of 51.2 Gy which is about 1.5 Gy lower than
the 52.7 Gy calculated for a schedule of 40.05 Gy in 15 fractions
followed by a boost of 10 Gy in 4 fractions. The differences in
D02 and D05 observed in this study are much larger; the doses
are about 4 Gy lower in the SIB arm. Using an a/b of 3 Gy for late
side effects, this corresponds with an EQD2 of 57.3 Gy in the SIB
arm, which is about 1 Gy higher than the EQD2 of 56.4 Gy in the
SeB arm. Yet, the calculated D02 and D05 are lower in the SIB
group even if an a/b of 3 Gy is used (Supplementary table). Fig. 3
nicely illustrates the difference in dose distribution between a
SeB and a SIB plan. The high-isodose lines in the SIB patient are
confined to the boost volume with dose decrease in the first
2 cm around the CTVboost, whereas in the SeB patient, high dose
regions are spread out over a larger part of the breast on the trans-
verse slice. There were no significant differences observed in EQD2
doses for heart and ipsilateral_lung.
The first follow-up visit after treatment was set at 10–14 days
after the last radiation session based on our experience with the19-fractions schedule. The next follow-up visit was scheduled at
6 months to limit the burden for the patients. However, patients
were advised to contact the investigators if toxicity got worse. In
that case they were invited for a follow-up visit. There is a chance
that toxicity presenting later than 10–14 days has been missed, but
Fig. 4 is reassuring. At last follow-up the frequency of pruritus and
oedema was declining and more case of grade 0 dermatitis were
seen. The evolution of grade 2 dermatitis and moist desquamation
was, however, different in both arms: while it was declining in the
SeB arm after treatment, the incidence was comparable in week 3
and after treatment in the SIB arm. The fact that during boost deliv-
ery in the SeB group (week 4 of treatment), the whole-breast is no
longer irradiated might be a possible explanation.
We acknowledge that the scoring of toxicity in this study has
some limitations. First, the treatment arm was not blinded to the
observer scoring toxicity. Second, grading of toxicity is often sub-
jective. We tried to counter this by choosing a more objective end-
point, i.e. moist desquamation, as the primary endpoint. The
difference between grade 1 and grade 2 dermatitis, i.e. faint ery-
thema versus moderate to brisk erythema, is far more subjective.
For the same reason, other endpoints like fatigue, pain, pruritus
and oedema were dichotomized to present or absent. Evaluation
of toxicity was done either by a dedicated study nurse (AVG) or a
limited number of radiation oncologists (FL, CM, TM, PB or LV),
all receiving training on toxicity scoring prior to the study.
Long term outcome results of SIB techniques for breast radio-
therapy have to be awaited. Five-year local control seems promis-
ing [14,15], but randomized data are not available. Since the same
EQD2 is delivered in a shorter time span, there is, however, no
36 RCT prone breast irradiation with SIBreason to assume that local control or overall survival will be
worse after a SIB than after a SeB. Late skin toxicity and cosmesis
will further be observed in this patient cohort.
Conclusion
No difference was observed between treatment arms in the rate
of moist desquamation, the primary endpoint of the trial. A SIB in
combination with prone hypofractionated WBI appears to be a safe
treatment regarding acute toxicity, but long-term data have to be
awaited.
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